The contraceptive transdermal patch is small, round and transparent and contains 2.1 mg gestodene and 550 micrograms ethinylestradiol. Each transdermal patch releases 60 micrograms gestodene per 24 hours and 13 micrograms ethinylestradiol per 24 hours. It is applied once a week either to the abdomen, buttocks or outer upper arm where it delivers a steady, continuous dose of hormones over the seven day application period. The systemic exposure is equal to oral doses as observed after daily administration of a combined oral contraceptive containing 60 micrograms gestodene and 20 micrograms ethinylestradiol. Each patch is replaced after seven days, and after three weeks, there is a hormone-free week.
The data from clinical studies, including 4,200 women worldwide, show that the new low dose contraceptive patch is an efficacious contraceptive with a good safety profile.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 54,900 employees (Dec 31, 2012) and is represented in more than 100 countries.